Overview

* Orthofix Q3 net sales rose 5% yr/yr to $205.6 mln, beating analyst expectations

* Adjusted EBITDA for Q3 increased 28.2% yr/yr, beating analyst estimates

* Company narrowed full-year net sales guidance, raised low end of adjusted EBITDA guidance

Outlook

* Orthofix narrows 2025 net sales guidance to $810 mln-$814 mln

* Orthofix raises low end of 2025 adjusted EBITDA guidance to $84 mln-$86 mln

* Orthofix expects positive free cash flow for 2025, excluding M6 restructuring charges

Result Drivers

* SPINE FIXATION GROWTH - U.S. Spine Fixation net sales grew 8%, driven by 7D FLASH™ navigation technology

* BONE GROWTH THERAPIES - Bone Growth Therapies net sales increased by 6% due to effective cross-selling and leveraging access points

* ORTHOPEDICS LAUNCH - U.S. Orthopedics net sales grew 19%, aided by the launch of TrueLok™ Elevate

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Beat $205.60 $200 mln

mln (5

Analysts

)

Q3 EPS -$0.57

Q3 Beat $24.60 $20.19

Adjusted mln mln (5

EBITDA Analysts

)

Q3 Gross 72.20%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for Orthofix Medical Inc ( OFIX ) is $23.00, about 30.2% above its November 3 closing price of $16.06

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)